Expert & agile partner offering CDMO services


Skyepharma is the oral business Unit of the Vectura Group of Companies (LSE: VEC), an industry-leading device and formulation company specialized in airways disease : www.vectura.com

As a fully integrated CDMO, Skyepharma offers early formulation development, scale-up, manufacturing and packaging of classic and complex oral solid dosage forms .

  • 1996 : Creation of Skyepharma
  • 30 years of experience in oral solid dosage forms
  • More than 110 employees including 1/4 in development department
  • Located near Lyon, FRANCE
  • Fully integrated CDMO since 2016
  • Pharmaceutical Industry
  • Food supplement Industry
  • Develoment, Manufacturing and Packaging of classic & complex oral solid forms
  • EU GMP certified facilities
  • FDA approved since 1998. Last inspection in september 2019
  • ANVISA approved since 2013
  • Registered at Korean MFDS
  • Products commercialized in US, EU, Brazil and Asia
  • 40% of products exported to the US market
  • March 2019 : 1st batch serialized and aggregated for US market


Millions blisters per year


Millions Bottles per year


Millions capsules per year


Millions tablets per year

Mission & vision


Skyepharma’s mission is to provide product development, manufacturing and packaging services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships.

Our vision is Solving healthcare industry complexity.

Expertise and Agility


Skyepharma is deeply committed in performance management and value creation for its clients. Service offering is continuously improved to propose state-of-the-art global development, manufacturing and packaging services.

Our partners can rely on our agility and scientific expertise resulting in accelerated time to market and maximized value across all pharmaceutical lifecycle stages.